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PLINICAL RESEARCH Interventional Cardiology
alue of Platelet Reactivity in Predicting
esponse to Treatment and Clinical Outcome
n Patients Undergoing Primary Coronary Intervention
nsights Into the STRATEGY Study
ianluca Campo, MD,* Marco Valgimigli, MD, PHD,*‡§ Donato Gemmati, MS,†
ianfranco Percoco, MD,* Silvia Tognazzo, MS,† Giordano Cicchitelli, MD,* Linda Catozzi, MS,†
atrizia Malagutti, MD,* Maurizio Anselmi, MD, Corrado Vassanelli, MD, Gianluigi Scapoli, MD,†
oberto Ferrari, MD, PHD*‡
errara, Gussago, and Verona, Italy; and Rotterdam, the Netherlands
OBJECTIVES The purpose of this study was to evaluate the value of platelet reactivity (PR) in predicting the
response to treatment and outcome in patients with ST-segment elevation myocardial
infarction (STEMI) undergoing primary percutaneous coronary intervention assisted by
glycoprotein (GP) IIb/IIIa inhibition.
BACKGROUND There is limited prognostic information on the role of spontaneous or drug-modulated PR in
STEMI patients.
METHODS The PR was measured with Platelet Function Analyzer (PFA)-100 and light transmission
aggregometry (LTA) using adenosine diphosphate as agonist in 70 consecutive STEMI
patients at entry (PR-T0), 10 min after GP IIb/IIIa bolus (PR-T1), and discharge (PR-T2)
and in 30 stable angina (SA) patients (PR-SA). Complete platelet inhibition (CPI) was based
on closure time 300 s by PFA-100 and percentage inhibition of platelet aggregation 95%
by LTA. Clinical, electrocardiographic, and angiographic responses to treatment during
1-year follow-up were collected.
RESULTS According to both techniques, PR-T0 was higher than: 1) PR-T2 and PR-SA; 2) in those
without CPI at T1; and 3) in patients with final Thrombolysis In Myocardial Infarction
(TIMI) flow grade 3. The PR-T0 assessed with PFA-100 correlated with: 1) corrected
TIMI frame count (r  0.6, p  0.001); 2) ST-segment resolution (r  45, p  0.001);
and 3) creatine kinase-MB (r  0.47, p  0.001). At 1 year, patients with high PR-T0
showed an adjusted 5- to 11-fold increase in the risk of death, reinfarction, and target vessel
revascularization (hazard ratio [HR] 11, 95% confidence interval [CI] 1.5 to 78 [p  0.02]
in PFA-100; HR 5.2, 95% CI 1.1 to 23 [p  0.03] in LTA).
CONCLUSIONS The PR at entry affects response to GP IIb/IIIa inhibition, mechanical treatment, and
long-term outcome in STEMI patients undergoing primary intervention. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.085Cardiol 2006;48:2178–85) © 2006 by the American College of Cardiology Foundation
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hlatelet activation, by favoring thrombus formation and
oronary artery occlusion, is thought to play a key pathoge-
etic role in acute myocardial infarction. Percutaneous
oronary intervention (PCI) is currently considered the
referred reperfusion strategy for patients with ST-segment
levation myocardial infarction (STEMI) (1). Recent evi-
ence strongly argues in favor of glycoprotein (GP) IIb/IIIa
nhibition in this setting (2) and reinforces the concept that
latelet reactivity (PR) is a potential target of treatment
eyond pure mechanical intervention.
From the *Department of Cardiology and †Center for the Study of Hemostasis and
hrombosis, University of Ferrara, Ferrara, Italy; ‡Cardiovascular Research Center,
alvatore Maugeri Foundation, IRCCS, Gussago, Italy; §Erasmus Medical Center,
horaxcenter, Rotterdam, the Netherlands; and the Dipartimento di Scienze
iomediche e Chirurgiche, Cardiologia, Verona, Italy. Supported in part by a grant
rom the Fondazione Cassa dei Risparmi di Ferrara (Italy).s
Manuscript received October 3, 2005; revised manuscript received December 5,
005, accepted December 19, 2005.In previous studies, PR has been used to evaluate the risk
f adverse events (3) and the extent of myocardial necrosis
4). Moreover, the importance of achieving a high level of
latelet inhibition early after GP IIb/IIIa bolus in non-
TEMI patients has been reported (5).
Whether baseline and/or drug-modulated PR influences
esponse to treatment and myocardial injury in STEMI pa-
ients undergoing primary PCI with GP IIb/IIIa inhibition is
nknown. This might further extend the current paradigm linking
latelet activation to outcome in the STEMI population.
To explore this hypothesis, PR was measured before,
uring, and after treatment as part of a pre-specified
ubstudy of the STRATEGY (Single High-Dose Bolus
irofiban and Sirolimus-Eluting Stent Versus Abciximab
nd Bare-Metal Stent in Acute Myocardial Infarction) trial
6–7). To address the issue whether high baseline PR is a
allmark of clinical acuity, a matched population affected by
table angina (SA) was also investigated.
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tudy population. One hundred patients treated with PCI
n the catheterization laboraty of the University Hospital of
errara were enrolled. The study population comprised 70
onsecutive patients (68% male, mean age 63  12 years)
ith STEMI (STEMI group) enrolled in a previously
eported trial (6) and 30 age- and gender-matched patients
ith SA (SA group) treated with PCI (67% male, mean age
4  6 years) (Table 1). The study was approved by the
ocal ethics committee, and all patients gave written in-
ormed consent.
edications, procedures, and assays. The design of the
TRATEGY trial has been previously reported (6–7).
riefly, patients with STEMI were randomly assigned to
ingle high-dose bolus (SHDB) tirofiban (25 g/kg/3 min,
ollowed by an infusion of 0.15 g/kg/min for 18 to 24 h)
r abciximab (bolus of 0.25 g/kg/3 min, followed by a
2-h infusion 0.125 g/kg/min). The study drug was
tarted in the intensive cardiac care unit. Per protocol,
atients randomized to tirofiban received sirolimus-eluting
tents (SES), whereas those allocated to abciximab received
are-metal stents (BMS). All patients received aspirin (250
g intravenously followed by 100 mg/day), clopidogrel (300
g followed by 75 mg/day), heparin (50 to 70 U/kg with
dditional bolus if necessary), and other treatments as
Abbreviations and Acronyms
CADP-CT  cartridge ADP closure time
CPI  complete platelet inhibition
LTA  light transmission aggregometry
PA  platelet aggregation
PCI  percutaneous coronary intervention
PR  platelet reactivity
SA  stable angina
STEMI  ST-segment elevation myocardial
infarction
able 1. Baseline Characteristics of the Patients
Characteristic
SHDB Tirofiban Group
(n  35)
A
ge (yrs) 64  13
en, n (%) 22 (63)
iabetes, n (%) 7 (20)
ypertension, n (%) 23 (66)
moker, n (%) 10 (28)
edical history
CABG, n (%) 0 (0)
PCI, n (%) 0 (0)
Acute myocardial infarction, n (%) 2 (6)
aboratory values at entry
Platelet count (U/ml) 241  45
Hematocrit (%) 40  5
White blood count (U/ml) 11.9  4
Fibrinogen (mg/dl) 420  162
Creatinine clearance (ml/min) 85  38ABG  coronary artery bypass graft; PCI  percutaneous coronary intervention; SA 
yocardial infarction.uggested by current guidelines. Patients with SA were
reated with aspirin and received, at least 6 h before
rocedure, 300 mg of clopidogrel.
ngiographic analysis. The angiographic images were ac-
uired with a General Electric Advantage CRS V 5.6.5
Fairfield, Connecticut) single-plane system at a cine rate of
5 frames/s before and immediately after the procedure.
ngiograms were analyzed by 1 experienced interventional
ardiologist blinded to the platelet assay results. All angio-
rams were assessed with a respect to Thrombolysis In
yocardial Infarction (TIMI) flow scale in the infarct-
elated artery (IRA) at baseline and after PCI (8). The
orrected TIMI frame counts (CTFC) and the myocardial
lush grade (MBG) were determined on a final angiogram
s described previously (9–10). No reflow was defined as
IMI flow grade 0 or I despite successful ballon angioplasty
r stent insertion, in spite of residual stenosis 50%,
bsence of significant dissection, or visible thrombus or
pasm in the IRA. Procedural success was defined as the
chievement of a final 30% residual stenosis and TIMI
ow grade 3.
lood sample collection. In the STEMI group, 3 blood
amples were performed: at entry (T0) before treatment, 10
1) min after the GP IIb/IIIa inhibitors bolus (T1), and at
ischarge (T2) (7  3 days). In the SA group, blood was
rawn before PCI procedure and clopidogrel intake (T0).
latelet function testing. Platelet function was measured
ith Platelet Function Analyzer-100 (PFA-100) (Dade
ehring, Miami, Florida), a U.S. Food and Drug
dministration-approved device, and with light transmis-
ion aggregometry (LTA).
FA-100. In the PFA system (11) blood is forced to flow
hroughout a synthetic capillary (147 m diameter), with a
ollagen and adenosine 5=-diphosphate (ADP)– coated
embrane with a central hole at its end (CADP cartridge,
0 g ADP and 2 g type 1 equine collagen). When a
ab Group
 35) p Value
STEMI Group
(n  70)
SA Group
(n  30) p Value
 12 0.6 63  12 64  6 0.3
(74) 0.2 48 (68) 20 (67) 0.5
(17) 0.5 13 (18) 6 (20) 0.5
(60) 0.4 44 (63) 20 (66) 0.4
(46) 0.1 26 (37) 11 (36) 0.6
(0) 0.9 0 (0) 2 (6) 0.09
(3) 0.5 1 (1.5) 0 (0) 0.7
(6) 0.7 4 (6) 4 (13) 0.2
 100 0.5 247  97 251  91 0.8
 4 0.2 41  5 42  6 0.6
 3 0.8 12  4 8  3 0.01
 116 0.4 407  139 400  129 0.7
 28 0.9 85  33 82  28 0.8bcixim
(n
63
26
6
21
16
0
1
2
254
41
12.1
395
84stable angina; SHDB  single high-dose bolus; STEMI  ST-segment elevation
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Platelet Reactivity in STEMI December 5, 2006:2178–85emostatic platelet plug completely obliterates the central
ole, the blood flow stops. The time necessary to stop the
ow is called “closure time” (CADP-CT) and inversely
eflects platelet reactivity. Its reference range in the absence
f antiplatelet therapy is 69 to 130 s (11–12). This instru-
ent confines detection of closure to a 300-s window and,
s a result, “nonclosure” is obtained. This degree of platelet
nhibition corresponds to 90% inhibition of platelet ag-
regation by means of light transmission aggregometry (20
mol/l ADP) (12–13). The CADP cartridge was selected
n the present study to monitor the effect of GP IIb/IIIa
nhibitors on platelet function based on available evidence
12,13).
IGHT TRANSMISSION AGGREGOMETRY. Blood was centri-
uged (200 g  10 min) to obtain platelet-rich plasma
PRP). The platelet count in PRP was adjusted to the range
f 150,000 to 300,000/l by dilution with autologous plasma
hen out of range. The remaining specimen was recentri-
uged (1,500 g  15 min) to obtain platelet-poor plasma
PPP). Platelets were stimulated with 20 mol/l ADP.
ggregation was measured at 37°C with a PACKS-4
ggregometer (Helena Laboratories, Beaumont, Texas)
nd expressed as the maximal percentage change in light
ransmittance from baseline at 5 min after the addition of
he agonist, with PPP as a reference. Percentage inhibition
f platelet aggregation (%IPA) was determined by the
ollowing formula: (%PA at baseline  %PA 10 min after
P IIb/IIIa)/%PA at baseline.
All samples for analysis were collected into evacuated
ubes containing 3.8% trisodium citrate and in evacuated
ubes containing D-Phe-Pro-Arg-chloromethylketone
PPACK). All measurements were done 0.5 to 1 h after
lood sampling. The CADP-CT measurements with citrate
nd PPACK were highly correlated (r  0.96, p  0.001).
oefficients of variation for duplicate analysis averaged 4%.
t baseline, CADP-CT correlated with aggregability mea-
ured with LTA (r  0.95, p  0.001). All patients who
ailed to achieve nonclosure at T1 showed %IPA 95%.
omplete platelet inhibition (CPI) was defined as
ADP-CT 300 s (nonclosure) and %IPA 95%.
tudy end points. To test the role of spontaneous and
rug-modulated PR, platelet function was related to: 1)
ngiographic evaluation (TIMI flow grade, incidence of no
eflow, CTFC, MBG, and procedural success rate); 2)
xtent of myocardial necrosis; 3) ST-segment resolution;
nd 4) clinical outcome. Extent of myocardial necrosis was
ssessed by creatine kinase-MB (CK-MB) (ng/dl) and
roponin I (TnI) (ng/dl) at peak. Cumulative ST-segment
levation, evaluated in all leads with any ST-segment
levation 1 mm, was measured to the nearest 0.5 mm at
0 min after the J point with the aid of hand-held calipers.
he clinical end points were death, reinfarction, target
essel revascularization (TVR) (major adverse cardiac events
MACE]), and angiographically confirmed stent thrombo-
is (ST). (tatistical analysis. Continuous data are presented as
ean values  SD, with the significance of differences
udged by t test. Because results of PFA-100 and LTA were
oth not normally distributed by Kolmogorov-Smirnov
oodness-of-fit test, the Mann-Whitney test was used to
ompare PR values between groups. Kruskal-Wallis analysis
f variance was used to compare more than 2 groups of
atients and to generate p values for trend tests for the
istribution of CK-MB and troponin levels according to
latelet reactivity quartiles. Categoric variables were sum-
arized in terms of number and percentages and were
ompared using 2-sided Fisher exact test. Spearman’s cor-
elation coefficients were used to detect any association
etween variables. Linear regression analysis was used to
est association between PR and variables reported in Table
. Survival curves were constructed by the Kaplan-Meier
ethod, and survival among groups was compared using the
og rank test. Cox proportional hazards models were used to
ssess risk reduction of adverse events. Multivariate analysis,
onsidering all clinical or angiographic variables differently
istributed (using p  0.10 as a threshold) according to
edian value of CADP-CT at entry, was performed to
dentify whether PR is an independent predictor for adverse
vents at 1 year. Probability was considered to be significant
t a level of 0.05. Analysis was performed using Statistica
.1 (Statsoft, Tulsa, Oklahoma).
ESULTS
aseline and procedural data of the study population are
hown in Tables 1 and 2. Patients with SA, recruited in
ebruary to March 2004, were well matched for age, gender,
nd all risk factors with respect to STEMI patients. Be-
ween January and April 2004, 70 STEMI patients, ran-
omly allocated to receive tirofiban or abciximab, were
rospectively enrolled in the present analysis. Their baseline
nd procedural characteristics did not differ from those
nrolled in the cohort of the STRATEGY trial (6). Sixty-
ix patients (94%) were treated with stent implantation, and
patient per group received only balloon angioplasty. In 1
atient in the SHDB tirofiban group, coronariography was
ot followed by treatment owing to both prompt restoration
f TIMI flow grade 3 after intracoronary nitrates injection
nd absence of coronary obstruction, whereas in 1 patient in
he abciximab group, type I aortic dissection determining
cclusion of the right coronary artery was followed by
mergent surgery.
latelet reactivity assays. The PR before any treatment,
valuated in terms of both CADP-CT (76  11) and %PA
90  5) was higher in STEMI than in SA patients (96 
and 50  6; p  0.01 for both) (Fig. 1). The CADP-CT
r %PA at entry was not related to any of the variables in
able 1. At entry, there were no differences between
irofiban and abciximab in terms of CADP-CT (77 11 vs.
4  12; p  0.3) or %PA (89  4 vs. 90  4; p  0.5)
Fig. 1). Overall, 4 patients were assuming aspirin as chronic
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December 5, 2006:2178–85 Platelet Reactivity in STEMIreatment before entry. Their PR did not differ in terms of
FA-100 or LTA at T0 or T1 compared with aspirin-naive
atients.
At T1, 31 of 35 patients (89%) treated with tirofiban
ersus 30 of 35 (86%) receiving abciximab reached the CPI
able 2. Procedural Data
Characteristic
SHDB Tirofiban Group
(n  35)
reated artery, n (%)
Left anterior descending 10 (29)
Right coronary 15 (44)
Circumflex 9 (27)
P IIb/IIIa-to-balloon (min) 35  7
CI successful, n (%) 30 (88)
eference diameter, pre (mm) 2.7  0.6
otal stent length (mm) 27  17
ominal stent diameter (mm) 3  0.5
tent implantation, n (%) 33 (94)
IMI flow, n (%)
Preprocedure
Grade 0 or 1 28 (80)
Grade 2 5 (14)
Grade 3 2 (6)
Postprocedure
Grade 0 or 1 2 (6)
Grade 2 1 (3)
Grade 3 31 (91)
o reflow, n (%) 2 (6)
ST-segment resolution 50%, n (%) 31 (88)
ST-segment resolution 70%, n (%) 20 (57)
K-MB at peak (ng/ml) 210  187
roponin I at peak (ng/ml) 85  77
P IIb/IIIa  start of GP IIb/IIIa inhibitors;   cumulative; other abbreviations
igure 1. Platelet reactivity assays. Solid squares  patients with stable
ngina (SA); open squares  patients with ST-segment elevation myo-
ardial infarction (STEMI); solid circles  abciximab subgroup; open
ircles  single high-dose bolus (SHDB) tirofiban subgroup. CADP m
artridge adenosine diphosphate closure time; T0  baseline; T1  10 min
fter glycoprotein IIb/IIIa bolus; T2  discharge.p  0.5). In the remaining 9 patients, CADP-CT was
98 s (297 to 299 s) in the 4 who received tirofiban and
94 s (292 to 296 s) in the 5 who received abciximab (p 
.06), whereas %PA was 11  2 vs. 14  4 (p  0.3),
espectively. In these 9 patients, baseline PR was signifi-
antly higher than in those reaching CPI at T1 (CADP-
T: 65  12 vs. 77  10, p  0.002; %PA: 93  4 vs. 89
4, p  0.003). Out of all variables included in Table 1,
nly PR at T0 was related to PR at T1. At discharge (7 
days), PR was lower than at entry in the STEMI group
CADP-CT: 76  11 vs. 98  8; p  0.001), which was
onfirmed by LTA findings (Fig. 1).
latelet reactivity and angiographic data. Baseline PR,
easured as CADP-CT and %PA (Fig. 2), was higher in
atients with TIMI flow grade 0/1 compared with those
ith TIMI flow grade 2/3 at first angiogram (p  0.001 for
oth). Among patients in whom angioplasty was attempted
68 patients), procedural success was reached in 61 (90%):
n 3 patients, a final TIMI flow grade 2 was obtained
espite repeated administration of intracoronary vasodilata-
ors; in another 3, an irreversible no-reflow phenomenon
fter stent implantation was observed; and in the remaining
atient, a distal macroembolization in a posterolateral
ranch occurred after vessel wiring. In these 7 patients,
aseline CADP-CT was lower (66  7 vs. 77  11; p 
.01) and %PA higher (93  4 vs. 89  4; p  0.02) than
n those with procedural success. Four (44%) of the 9
atients who failed to achieve the CPI at T1 had an
nsuccessful intervention compared with 3 (5%) in whom
iximab Group
(n  35)
p
Value
STEMI Group
(n  70)
SA Group
(n  30)
p
Value
17 (49) 0.07 27 (40) 14 (47) 0.3
13 (38) 0.4 28 (41) 6 (20) 0.04
4 (13) 0.1 13 (19) 10 (33) 0.4
37  10 0.7 36  10 — —
31 (92) 0.5 61 (88) 30 (100) 0.07
2.8  0.5 0.7 2.7  0.5 2.8  0.6 0.6
29  15 0.6 28  16 30  15 0.2
3  0.4 0.6 3  0.4 3  0.7 0.8
33 (94) 0.7 66 (94) 30 (100) 0.2
30 (86) 0.4 58 (83) 0 (0) 0.01
4 (11) 0.5 9 (13) 8 (27) 0.08
1 (3) 0.5 3 (4) 22 (73) 0.01
1 (3) 0.5 3 (4) 0 (0) 0.3
2 (6) 0.7 3 (4) 0 (0) 0.2
31 (91) 0.5 62 (91) 30 (100) 0.07
1 (3) 0.5 3 (4) 0 (0) 0.3
29 (83) 0.3 60 (86) — —
17 (48) 0.3 37 (53) — —
227  154 0.7 218  170 — —
108  95 0.3 97  87 — —
able 1.Abcaximum platelet inhibition was obtained (p  0.004).
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Platelet Reactivity in STEMI December 5, 2006:2178–85atients showing no reflow had enhanced PR (CADP-CT:
2  7 vs. 77  11, p  0.03; %PA: 95  3 vs. 89  4, p
0.02). None of them reached the CPI at T1. The
ADP-CT and %PA at entry was related to CTFC both in
ll patients receiving intervention (r  0.6, p  0.001)
nd in those with final TIMI flow grade 3 (r  0.53, p 
.001). Patients with MBG 2/3 tended to have lower PR
ompared with those with MBG 0/1 (CADP-CT: 77  11
s. 71  11, p  0.06; %PA: 89  5 vs. 91  4, p  0.05).
latelet reactivity and ST-segment resolution. The
ADP-CT and %PA at baseline was directly correlated to
he degree of ST-segment resolution immediately after the
rocedure (r  0.45 and r  0.42, respectively; p  0.001
or both). The PR at entry was higher in patients without
umulative ST-segment resolution 50% (CADP-CT: 67
10 vs. 78  11, p  0.001; %PA: 93  4 vs. 89  4, p
0.003) or 70% (CADP-CT: 72  11 vs. 80  11, p 
.007; %PA: 91 4 vs. 88 3, p 0.006). Four (44%) and
even (78%) among the 9 patients who failed to achieve CPI
id not reach ST-segment resolution 50% or 70%
ompared with 7 (12%) and 24 (41%) of the 59 with CPI (p
0.03 and p  0.04, respectively).
latelet reactivity and infarct size. The CADP-CT at T0
as inversely correlated with CK-MB and TnI at peak in
igure 2. Relationship between Thrombolysis In Myocardial Infarction
TIMI) flow grade before percutaneous coronary intervention (PCI) and
aseline cartridge adenosine diphosphate (CADP) closure time (CADP-
T). Lower TIMI flow at first angiogram was associated with higher
latelet reactivity (PR). CADP-CT was 73  11 in the TIMI flow grade
/1 group versus 87  8 in the TIMI flow grade 2/3 group (p  0.001),
nd % platelet aggregation was, respectively, 91  4 versus 85  3 (p 
.001). CADP-CT was 75  11 in the TIMI flow grade 0/1/2 group
ersus 89  6 in the TIMI flow grade 3 group (p  0.03), and %PA was,
espectively, 90  4 versus 84  2 (p  0.01).atients with STEMI (r  0.47, p  0.001 and r 
t
a0.48, p  0.001, respectively). CK-MB and Tn I at peak
ccording to CADP-CT quartiles are shown in Figure 3.
ll data were confirmed by LTA (data not shown).
latelet reactivity and clinical outcome. Complete follow-up
nformation up to 365 days was available for all patients. In
he SA group, no adverse event was observed. In the
TEMI group at 30 days, 3 deaths and 2 reinfarctions
ccurred owing to subacute ST, which required urgent
VR. At 1 year, 13 patients (18%) experienced adverse
vents, including 4 deaths, 4 reinfarctions (2 due to ST), and
TVR (2 urgent).
At entry, patients with MACE at 30 days, compared with
hose without, had higher PR at T0 (CADP-CT: 57 8 vs.
7  10, p  0.001; %PA: 97  4 vs. 89  4, p  0.001)
Fig. 4). Of note, the 2 patients who had ST failed to
chieve CPI at T1.
Patients with MACE within 1 year had lower
ADP-CT at entry (65  9 vs. 78  11; p  0.001) and
igher %PA (94  3 vs. 89  4; p  0.001) than those
ith uneventful follow-up (Fig. 4). The cumulative
ncidence of MACE was significantly lower in patients
ith high (above median value, low PR) compared with
hose with low (below median value, high PR)
ADP-CT at T0 (3% vs. 34%; p  0.0006). The patients
n the high-reactivity group showed a 12-fold increase in
he risk of composite end point (hazard ratio [HR] 12,
5% confidence interval [CI] 2.7 to 125; p  0.0009)
Fig. 5). As shown in Table 3, there were no statistically
ignificant differences between groups with the exception
igure 3. Peak plasma levels of creatine kinase-MB (CK-MB) (top) and
roponin I (bottom) are shown according to quartiles (Q) of CADP closure
t admission. CADP-CT  cartridge adenosine diphosphate closure time.
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December 5, 2006:2178–85 Platelet Reactivity in STEMIf percentage of diabetes mellitus, which was higher in
he high-PR subgroup (10% vs. 3%; p  0.03). Including
iabetes, at multivariate analysis PR remained an inde-
endent predictor for MACE (HR 11, 95% CI 1.5 to 78;
 0.02). Based on LTA, there was an adjusted 5-fold
ncrease in the risk of MACE (HR 5.2, 95% CI 1.1 to 23;
 0.03) in the high-reactivity group.
igure 4. Cartridge adenosine diphosphate (CADP) closure time stratified
n relation with the clinical outcome at 30 days and at 1 year. Solid circles
patients that not reached the composite end point; open circles 
atients that reached the composite end point. MI  myocardial infarc-
ion; TVR  target vessel revascularization.
igure 5. Probability of major adverse cardiac events (MACE) in patients
latelet reactivity  CADP-CT at entry below the median value. Low platelet r
ADP-CT is 75 s. Abbreviations as in Figures 1 and 2.At discharge, PR tended to be higher in patients with
ompared with those without adverse events at follow-up
CADP-CT: 94  8 vs. 98  8, p  0.2; %PA: 18  6 vs.
5  5, p  0.1).
ISCUSSION
latelet reactivity is pivotal in the pathogenesis of acute
oronary syndromes (ACS) and it is a well known predictor
or adverse outcome after PCI (3). Accordingly, inhibitors
f GP IIb/IIIa decrease incidence of adverse events both in
he PCI setting (14) and in patients with ACS (15).
The three major findings of the present study are:
. Patients with STEMI have higher PR than patients
with SA.
. Baseline PR affects the response to GP IIb/IIIa inhib-
itors soon after bolus.
. The PR at baseline and, consecutively, after GP IIb/IIIa
inhibitor bolus influences the angiographic success of
the procedure as well as the degree of ST-segment
resolution, the extent of myocardial necrosis, and the
short- and mid-term clinical outcome in patients un-
dergoing primary intervention.
ur data demonstrated that baseline PR is a hallmark of
linical acuity. This statement is mainly based on the finding
hat PR was higher in the STEMI than in the control group
patients with SA).
It has been demonstrated that the response to clopidogrel
s patient specific, with an important interindividual vari-
bility (16–17), and that the pre-treatment platelet activity
ould influence final response to clopidogrel (17). Recently,
case-control studies associated the enhanced platelet
ed according to PR measured with Platelet Function Analyzer-100. Highstratifi
eactivity  CADP-CT at entry above the median value. Median value of
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Platelet Reactivity in STEMI December 5, 2006:2178–85ggregation and the impaired responsiveness to antiplatelet
rugs with the stent thrombosis incidence (18,19). In our
rospective study, with a homogeneous patient population
n terms of ethnicity (all patients were Caucasian), clinical
resentation (STEMI), and treatment (primary PCI), we
onfirmed that there is an interindividual variability in PR.
his influences the response to antiplatelet therapy, also if
P IIb/IIIa inhibitors, the strongest currently available
ntiplatelet treatment, are used.
Our study population comprised 13 diabetics. In keeping
ith previous evidence (20), they showed increased PR: At
0, 10 out of 13 (77%) were in the high-PR subgroup (p 
.03 vs. nondiabetics); at T1, using both PFA-100 and
TA, 3 of 13 (23%) achieved incomplete platelet inhibition
ersus 6 of 57 (11%) in the nondiabetic group (p  0.26);
hereas at T2, CADP-CT in diabetics was lower (91  7
s. 99  8 in nondiabetics; p  0.01) and %PA higher (19
5 vs. 14  4 in nondiabetics; p  0.001). One of these
atients experienced ST at follow-up. Cumulatively, 5
iabetic patients out of 13 (38%) satisfied the composite end
oint (vs. 14% in nondiabetics; p 0.05). Thus, when taken
ogether with available evidence, the present data suggest
hat diabetes greatly contributes to overall interindividual
ariability in PR, and as such diabetics may be an ideal
arget population for tailored antiplatelet therapy in both
cute and chronic settings.
Failure to achieve TIMI flow grade 3, the no-reflow
henomenon, and higher CTFC values after reperfusion
herapy have been found to be associated with more exten-
ive myocardial necrosis and poor clinical outcome (21). In
able 3. Clinical, Biochemical, and Procedural Data of STEMI P
Characteristic
High Platelet Re
(n  35)
ge (yrs) 65  12
en, n (%) 13 (37)
iabetes, n (%) 10 (28)
ypertension, n (%) 23 (66)
moker, n (%) 12 (35)
edical history
CABG, n (%) 0 (0)
PCI, n (%) 0 (0)
Acute myocardial infarction, n (%) 1 (3)
aboratory values at entry
Platelet count (U/ml) 264  115
Hematocrit (%) 40  5
White blood count (U/ml) 12.4  4
Fibrinogen (mg/dl) 392  122
Creatinine clearance (ml/min) 82  29
rocedural data
Left anterior descending, n (%) 11 (32)
Right coronary, n (%) 16 (47)
Circumflex, n (%) 7 (21)
Reference diameter, pre (mm) 2.7  0.6
Total stent length (mm) 28  15
Nominal stent diameter (mm) 3  0.5
High platelet reactivity  closure time (CT) below the median value; low platelet r
Abbreviations as in Table 1.he current study, we demonstrated that TIMI flow grade l3, no reflow, and high CTFC occur significantly more
requently in patients with enhanced baseline PR.
As previously reported, the enhanced platelet function
orrelated with the degree of myocardial damage in the
resent study (4). Moreover, a clear association between PR
nd the degree of ST-segment resolution was found. This
nding may be critically relevant, because, in STEMI
atients treated with primary PCI, ST-segment reduction
as independently related to 6-month mortality (2).
In the present study, we studied PR using 2 methodolo-
ies. Light transmission aggregometry is still considered to
e the gold standard, but it has some disadvantages, such as
imited reproducibility and complex sample preparation.
onversely, PFA-100 is a rapid tool that can be used in the
linical practice to identify patients with higher PR, which
ould potentially be exploited as a means of tailoring the
ntiplatelet treatment to individual need. This may be
articularly relevant in the setting of primary intervention
or STEMI, when a short door-to-balloon time is needed
nd other biomarkers of PR may not available. Further
tudies are needed to establish the optimal bedside assay to
valuate the PR in this setting.
tudy limitations. Owing to limited sample size, our
rospective investigation should be regarded as exploratory.
n particular, to obtain a reliable estimate of the prognostic
apability of PR at entry and to evaluate whether the
esponse to GP IIb/IIIa inhibitors is an independent out-
ome predictor beyond PR at entry, a larger prospectively
ollected study population is clearly required. Recently, it
as been shown in elective patients that PR measured at
nts Stratified by Platelet Reactivity at Entry*
ity Low Platelet Reactivity
(n  35) p Value
62  12 0.4
9 (26) 0.2
3 (9) 0.03
21 (60) 0.4
14 (39) 0.4
0 (0) 0.9
1 (3) 0.5
3 (8) 0.3
232  76 0.2
41  4 0.2
11.6  3 0.4
422  155 0.4
85  35 0.3
16 (47) 0.2
12 (35) 0.3
6 (18) 0.5
2.8  0.5 0.7
28  17 0.9
3  0.4 0.6
ty  CT above the median value; median value of CT at entry is 75 s.atie
activeast 24 h after stenting independently predicts outcome
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December 5, 2006:2178–85 Platelet Reactivity in STEMI22). In the present study, PR at discharge failed to be
ignificantly associated with outcome; differences in patient
elections, timing of platelet assays, and limited statistical
ower may help explaining these different findings. The
FA-100 confines detection of closure to a 300-s window,
nd, because in most patients nonclosure is exhibited shortly
fter GP IIb/IIIa inhibitor administration, this device may
e suboptimal for properly identifying those individuals at a
igher risk for subsequent thrombotic events. Because this
as an issue in the present investigation, future studies with
igger sample size are clearly needed.
onclusions. In patients undergoing primary PCI for
TEMI, PR at entry was related to both angiographic and
lectrocardiographic response to treatment as well as to the
everity of cardiac injury as measured by the release of
arkers of cardiac necrosis. After 1 year, PR at presentation
ndependently predicted major cardiac adverse events.
hether modulating PR through tailored or systematic
ntiplatelet treatment overcomes the prognostic implica-
ions of spontaneous platelet function remains elusive and
ay warrant further investigations.
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